Phytoestrogens and prevention of breast cancer: The contentious debate

10.1289/ehp.10538

10.1177/0884533612456043

Gikas PD, Mokbel K. Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med 2005;50:250-258.

10.1387/ijdb.113369vp

10.1016/j.ejca.2008.05.019

10.1007/s10787-008-8020-0

10.3945/jn.110.124230

10.2217/14796694.3.3.307

10.1002/mnfr.200800478

10.1016/j.yfrne.2010.03.003

10.1007/s13318-012-0112-y

Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005;230:155-170.

10.1016/j.maturitas.2009.12.019

Karr SC, Lampe JW, Hutchins AM, Slavin JL. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am J Clin Nutr 1997;66:46-51.

10.1079/BJN2001424

Leclercq G, Jacquot Y. Interactions of isoflavones and other plant derived estrogens with estrogen receptors for prevention and treatment of breast cancer-considerations concerning related efficacy and safety. J Steroid Biochem Mol Biol 2014;139:237-244.

10.1677/erc.1.01159

10.1016/j.jsbmb.2011.06.003

10.1002/mnfr.201200439

10.1038/nrc3093

10.1007/s00280-005-0107-3

Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263.

10.3945/ajcn.2009.28854

10.1152/physrev.00026.2006

10.1016/j.mrfmmm.2005.04.010

10.1089/lrb.2009.0030

10.1016/j.jsbmb.2009.04.009

10.1038/onc.2012.261

10.1007/s12609-012-0083-7

10.1055/s-0032-1321818

10.3892/ijo_00000073

10.1093/carcin/bgq123

10.1016/j.jnutbio.2009.06.010

10.1093/hmg/ddi155

10.1016/j.nutres.2011.01.011

10.1158/0008-5472.CAN-04-3995

10.1038/nrc2347

10.1038/sj.onc.1203285

10.1242/jcs.00739

10.3892/mmr.2013.1283

10.1186/1475-2867-6-20

Privat M, Aubel C, Arnould S, Communal Y, Ferrara M, Bignon YJ. AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines. Anticancer Res 2010;30:2049-2054.

10.1002/ijc.25930

10.1007/s10549-007-9705-6

10.1101/cshperspect.a008656

10.1080/01635581.2011.606955

10.1016/j.lfs.2012.08.022

10.1186/1477-3163-5-15

Rajah TT, Peine KJ, Du N, Serret CA, Drews NR. Physiological concentrations of genistein and 17β-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Anticancer Res 2012;32:1181-1191.

10.1016/j.tiv.2008.08.001

Nguyen TH, Mustafa FB, Pervaiz S, Ng FS, Lim LH. ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Int J Oncol 2008;33:81-92.

10.1159/000103253

10.1016/j.jsbmb.2007.09.003

10.1016/j.canlet.2012.05.019

10.3389/fonc.2013.00250

10.1016/j.jsbmb.2005.02.007

10.1093/toxsci/kfh257

10.1186/1477-7827-9-91

10.1016/S0899-9007(00)00333-6

10.1016/j.jsbmb.2006.06.021

10.1186/bcr2925

10.1021/tx200378c

10.1016/j.jsbmb.2012.12.011

10.2217/epi.11.71

10.1007/s13148-010-0011-5

10.2217/epi.13.57

10.1371/journal.pone.0054369

10.1186/1476-4598-12-9

10.1089/omi.2011.0105

10.4048/jbc.2013.16.1.23

10.1016/j.jsbmb.2010.04.007